We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

141 hedge funds and large institutions have $843M invested in CytomX Therapeutics in 2018 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,438% more call options, than puts

Call options by funds: $2.72M | Put options by funds: $177K

160% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 15

32% more capital invested

Capital invested by funds: $637M → $843M (+$206M)

18% more funds holding

Funds holding: 119 → 141 (+22)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 43

1.44% less ownership

Funds ownership: 78.49% → 77.05% (-1.4%)

Holders
141
Holders Change
+22
Holders Change %
+18.49%
% of All Funds
3.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
39
Increased
42
Reduced
43
Closed
15
Calls
$2.72M
Puts
$177K
Net Calls
+$2.55M
Net Calls Change
+$2.58M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$69.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$10.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.5M
4
Renaissance Technologies
Renaissance Technologies
New York
+$7.02M
5
PC
PointState Capital
New York
+$4.4M

Top Sellers

Rank Fund Capital Flow
1
TG
TRV GP
Massachusetts
-$65.6M
2
BI
BVF Inc
California
-$23.7M
3
PA
Perceptive Advisors
New York
-$8.04M
4
Millennium Management
Millennium Management
New York
-$6.92M
5
PAG
Private Advisor Group
New Jersey
-$4.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
126
Federation des caisses Desjardins du Quebec
Quebec, Canada
$75.4K +$75.6K +2,650 New
AIP
127
Ameritas Investment Partners
Nebraska
$73K – – –
TRCT
128
Tower Research Capital (TRC)
New York
$52K +$51.9K +1,818 New
Canada Life
129
Canada Life
Manitoba, Canada
$51K – – –
MAM
130
Meeder Asset Management
Ohio
$44K +$22.2K +779 +105%
Fifth Third Bancorp
131
Fifth Third Bancorp
Ohio
$42K – – –
PCM
132
Prelude Capital Management
New York
$34K +$22.9K +802 +200%
QI
133
QS Investors
New York
$11K – – –
RA
134
Royce & Associates
New York
$6K -$4.02K -141 -39%
Daiwa Securities Group
135
Daiwa Securities Group
Japan
$6K +$6.05K +212 New
TDC
136
Thompson Davis & Co
Virginia
$4K – – –
AWMS
137
Advocacy Wealth Management Services
Georgia
$3K – – –
HLA
138
Hamilton Lane Advisors
Pennsylvania
$3K +$1.57M +55,139 +109%
Simplex Trading
139
Simplex Trading
Illinois
$2K +$2.54K +89 New
AssetMark Inc
140
AssetMark Inc
California
$1K – – –
BI
141
BVF Inc
California
– -$23.7M -1,124,483 Closed
PAG
142
Private Advisor Group
New Jersey
– -$4.19M -185,187 Closed
NC
143
Nexthera Capital
New York
– -$3.8M -179,870 Closed
Prudential Financial
144
Prudential Financial
New Jersey
– -$617K -29,210 Closed
Macquarie Group
145
Macquarie Group
Australia
– -$464K -22,000 Closed
AIMCA
146
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$422K -20,000 Closed
Parallax Volatility Advisers
147
Parallax Volatility Advisers
California
– -$93K -4,410 Closed
QT
148
Quantbot Technologies
New York
– -$65K -3,115 Closed
DCM
149
Delpha Capital Management
New York
– -$44K -2,106 Closed
PS
150
Portfolio Solutions
Michigan
– -$21K -1,001 Closed
3 4 5
6
7

CTMX Hedge Fund Activity: Q1 2018 in Review

141 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2018, worth a combined $843M — up 32% from $637M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CTMX positions and 15 closed out — a net gain of 24 holders — while 42 added to existing stakes and 43 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $69.7M. The largest seller was TRV GP, cutting an estimated $65.6M.

  • 141 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2018, up from 119 in Q4 2017.
  • Funds reported $843M of CytomX Therapeutics stock for Q1 2018, up 32% quarter-over-quarter.
  • 39 funds opened new CytomX Therapeutics positions in Q1 2018 and 15 closed out, a net change of +24 holders.
  • The largest CytomX Therapeutics buyer in Q1 2018 was T. Rowe Price Associates, an estimated $69.7M added.
  • The largest CytomX Therapeutics seller in Q1 2018 was TRV GP, an estimated $65.6M sold.

Based on aggregated 13F filings for Q1 2018.